Brain Tumor Treatment Market By Type 2022 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Brain Tumor Treatment Market
Brain Tumor Treatment Market: By Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Others); By Diagnosis (City Scan, Neurological Tests, MRI, Angigram, Others); By Geography - Forecast (2016-2022)
Report Code : HCR 0257
Updated Date: 14 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
A brain tumor is an abnormal growth of tissue in the brain which may be benign or malignant which cause damage to the brain and becomes life threatening. Severe headache, nausea, vomiting, blurred and double vision, personality or behavior changes, difficulties in hearing and speech are the symptoms of brain tumor. It occurs due to changes in DNA cells and exposure to radiation. Brain tumor is classified by grades such as Grade I, II, III and IV. Brain tumors are majorly classified into primary and secondary types. Technological advancements and increased R&D investments in the treatments and therapies for brain tumor propels the market growth during the forecast period 2016-2022. Brain tumor treatment market is poised to grow with XX% CAGR during the forecast period and reach $XXm by 2022.

Type of treatment is recommended based upon on the type, size and location of brain tumor. Various treatments for curing brain tumor are surgery, radiation therapy, and chemotherapy, immunotherapy and so on which reduce the symptoms and slow down the tumor’s growth. Chemotherapy is an alternative to radiation therapy in children with brain tumors due to its side effects. Researchers have been developed new techniques of delivering radiation that target the brain tumor while protecting nearby healthy tissues. Presence of brain tumour can be detected by Neorological tests, MRI, CT and Angiogram. High-energy radiation prevents the growth of acoustic neuromas.

Brain Tumor Treatment Market

By geography, America stands first in cases of brain tumor followed by Europe, APAC and RoW. Nearly 7,00,000 people in the U.S. are suffering with primary brain tumor and central nervous system tumor. More than 28,000 children are estimated to be living with a brain tumor in the U.S.

Sample companies profiled in this report are:
  • Genetech Inc. (U.S.)
  • Bristol Mayers squibb (U.S.)
  • Hoffmann-La Roche (Switzerland)
  • Astra Zeneca (India)
  • Pfizer Inc. (U.S.)
  • 10+.
1. Brain Tumor Treatment Market Overview
   1.1. Introduction
   1.2. Classification
2. Executive Summary
3. Brain Tumor Treatment Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. Patent Analysis
      3.2.3. Financials of Key Players
4. Brain Tumor Treatment Market Forces
   4.1. Market Drivers
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Market
      4.4.1. Suppliers Power
      4.4.2. Bargaining Power of Buyer
      4.4.3. Threat from New Entrants
      4.4.4. Threats from Substitutes
      4.4.5. Degree of Competition
5. Brain Tumor Treatment Market – Strategic Analysis
   5.1. Supply Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunity Analysis
6. Brain Tumor Treatment Market– By Type
   6.1. Surgery
   6.2. Radiation Therapy
   6.3. Chemotherapy
   6.4. Immunotherapy
   6.5. Others
7. Brain Tumor Treatment Market– By Diagnosis
   7.1. City Scan
   7.2. Neurological Tests
   7.3. MRI
   7.4. Angigram
   7.5. Others
8. Brain Tumor Treatment Market- By Geographic Analysis
   8.1. Introduction 
   8.2. North America
      8.2.1. U.S.
      8.2.2. Canada
      8.2.3. Mexico
   8.3. Europe
      8.3.1. U.K.
      8.3.2. Germany
      8.3.3. France
      8.3.4. Italy
      8.3.5. Rest of Europe
   8.4. APAC
      8.4.1. China
      8.4.2. Japan
      8.4.3. India
      8.4.4. NZ
      8.4.5. Rest of APAC
   8.5. RoW
      8.5.1. South America
      8.5.2. Middle East
      8.5.3. Africa
9. Brain Tumor Treatment Market Entropy
10. Company Profiles (Overview, Financials, Developments and Product Portfolio)  
        
   10.1. Genetech Inc. (U.S.)
   10.2. Bristol Mayers Squibb (U.S.)
   10.3. Hoffman-La Roche (Switzerland)
   10.4. Astra Zeneca (India)
   10.5. Pfizer Inc. (U.S.)
   10.6. Novartis Inc. (Switzerland)
   10.7. Antisenese Pharma (Mongolia)
   10.8. Merck & Co. (U.S.)
   10.9. Mcleod’s Pharmaceuticals Ltd. (India)
   10.10. Mankind Pharma (India)
   10.11. Dr. Reddy’s Laboratories (India)
*More than 10 Companies are profiled in this Research Report*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll